Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

100.0%

3 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 4
1(50.0%)
2Total
N/A(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02768532Phase 4Terminated

Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease

Role: collaborator

NCT03724929Not ApplicableTerminated

Value of Pharmacokinetic Assays in the Prediction of Therapeutic Response in Ulcerative Colitis

Role: collaborator

NCT02474888Terminated

Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis

Role: collaborator

All 3 trials loaded